培唑帕尼治疗中国晚期软组织肉瘤的回顾性研究

中华转移性肿瘤杂志（2021）

Cited 0|Views11

Abstract

目的:探索培唑帕尼治疗中国晚期软组织肉瘤(STS)患者的有效性及安全性。方法:收集2017—2018年间在中山大学肿瘤防治中心就诊的58例晚期STS患者使用培唑帕尼的临床特征、生存预后及疗效等资料进行回顾性分析。结果:所有患者均使用了培唑帕尼治疗，其中11例患者以培唑帕尼治疗作为一线治疗(19%)，24例患者作为二线治疗(41%)，23例患者作为三线及以上治疗(40%)。总体最佳客观缓解率为31%，疾病缓解率为76%，中位无进展生存期为5.1个月(95% CI为3.7～6.5)，中位总生存期为13.3个月(95% CI为8.0～18.7)。主要不良反应为毛发变白(95%)及手足综合征(83%)，大部分不良反应为轻度及中度。结论:培唑帕尼对中国晚期STS人群有效且毒性可耐受，部分不良反应及严重程度等表现出中国患者特征。

Translated text

Key words

Pazopanib,Soft tissue sarcoma,Chinese patients,Efficacy and safety

求助PDF

上传PDF

Bibtex

AI Read Science

AI Summary

AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.

Example

Background

Key content

Introduction

Methods

Results

Related work

Fund

Key content

Pretraining has recently greatly promoted the development of natural language processing (NLP)
We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance

Upload PDF to Generate Summary

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Chat Paper

【要点】：研究探讨了在中国晚期软组织肉瘤（STS）患者中使用帕唑帕尼治疗的疗效和安全性，结果显示疗效显著且毒性可耐受，具有中国特色的不良事件特点。

【方法】：通过回顾性分析2017至2018年间在中山大学肿瘤防治中心接受帕唑帕尼治疗的58例STS患者的临床特征、生存预后和疗效。

【实验】：所有患者均接受帕唑帕尼治疗，实验结果得出客观响应率为31%，疾病控制率为76%，中位无进展生存期为5.1个月，中位总生存期为13.3个月，最常见的不良事件为头发低色素沉着（95%）和掌跖红感觉异常综合征（83%），多数不良事件为轻微或中度。数据来源于中山大学肿瘤防治中心。